Treatment with danirixin did not demonstrate any meaningful clinical benefits in improving COPD symptoms or health-related quality of life, contrasting the results of earlier studies, indicating that patients with COPD might benefit from treatment with a CXCR2 antagonist. This evidence concerns the gene CXCR2 and chronic obstructive pulmonary disease.